Birchview Capital, LP
BURLINGTON, VT
$214m in 72 US stocks at the end of 30 June 2026. The top 10 are 59.9% of the money. It changed about 24.1% of the portfolio this quarter.
Value
$214m
Stocks
72
Top 10 share
59.9%
Turnover
24.1%
What changed this quarter
New
Bought for the first time this quarter.
- Abivax SAABVX1.1% of the fund
- Vir BiotechnologyVIR1.0% of the fund
- BioAge LabsBIOA0.8% of the fund
- Novo Nordisk A SNVO0.5% of the fund
- AdageneADAG0.5% of the fund
- Definium TherapeuticsDFTX0.4% of the fund
- Silence TherapeuticsSLN0.4% of the fund
- 4D Molecular TherapeuticsFDMT0.3% of the fund
- UroGen PharmaURGN0.3% of the fund
- Camp4 TherapeuticsCAMP0.2% of the fund
- SavaraSVRA0.2% of the fund
- AltimmuneALT0.2% of the fund
- Capricor TherapeuticsCAPR0.2% of the fund
- InvivydIVVD0.1% of the fund
Added
Bought more of a stock they already held.
- Solid BiosciencesSLDB3.1% of the fund+6%
- Nektar TherapeuticsNKTR2.6% of the fund+161%
- Corcept TherapeuticsCORT2.3% of the fund+21%
- Compass TherapeuticsCMPX1.7% of the fund+14%
- Halozyme TherapeuticsHALO1.2% of the fund+229%
- Vera TherapeuticsVERA1.2% of the fund+31%
- Zenas BioPharmaZBIO1.1% of the fund+34%
- BiogenBIIB0.9% of the fund+80%
- Quidel0.7% of the fund+8%
- Grace TherapeuticsGRCE0.1% of the fund+140%
Cut
Sold some of their stake.
- KLAKLAC25.2% of the fund-10%
- Bristol-Myers SquibbBMY8.0% of the fund-3%
- Lam ResearchLRCX7.1% of the fund-3%
- Intellia TherapeuticsNTLA3.2% of the fund-13%
- Stoke TherapeuticsSTOK2.7% of the fund-15%
- Olema PharmaceuticalsOLMA1.2% of the fund-9%
- uniQureQURE1.1% of the fund-50%
- Pacific Biosciences of CaliforniaPACB1.1% of the fund-10%
- Bicycle TherapeuticsBCYC0.6% of the fund-32%
- Structure TherapeuticsGPCR0.6% of the fund-76%
- Phathom PharmaceuticalsPHAT0.3% of the fund-72%
- Candel TherapeuticsCADL0.2% of the fund-20%
- COMPASS PathwaysCMPS0.2% of the fund-92%
- Karyopharm TherapeuticsKPTI0.2% of the fund-49%
- PulmonxLUNG0.1% of the fund-20%
- Ocular TherapeutixOCUL<0.1% of the fund-94%
- LipocineLPCN<0.1% of the fund-85%
Sold out
Sold their entire stake.
- NovoCureNVCR-100%
- Engene Holdings-100%
- Ultragenyx PharmaceuticalRARE-100%
- Kalvista Pharmaceuticals-100%
- VerastemVSTM-100%
- Apogee TherapeuticsAPGE-100%
- Apellis Pharmaceuticals-100%
- IDEAYA BiosciencesIDYA-100%
- Arcus BiosciencesRCUS-100%
- RegenxbioRGNX-100%
- Rocket PharmaceuticalsRCKT-100%
- Viridian TherapeuticsVRDN-100%
- Outset MedicalOM-100%
- PhreesiaPHR-100%
- Zentalis PharmaceuticalsZNTL-100%
Holdings
- Abivax SAABVX
- Share
- 1.1%
- Value
- $2m
- Shares
- 17,000
New
- Quidel
- Share
- 0.7%
- Value
- $2m
- Shares
- 89,377
+8%
- Bicycle TherapeuticsBCYC
- Share
- 0.6%
- Value
- $1m
- Shares
- 313,616
-32%
- Structure TherapeuticsGPCR
- Share
- 0.6%
- Value
- $1m
- Shares
- 24,000
-76%
- Quoin PharmaceuticalsQNRX
- Share
- <0.1%
- Value
- $96,800
- Shares
- 20,000
Held
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| KLAKLAC | 25.2% | $54m | 178,471 | -10% |
| Bristol-Myers SquibbBMY | 8.0% | $17m | 297,243 | -3% |
| Lam ResearchLRCX | 7.1% | $15m | 35,000 | -3% |
| Intellia TherapeuticsNTLA | 3.2% | $7m | 385,900 | -13% |
| Solid BiosciencesSLDB | 3.1% | $7m | 666,196 | +6% |
| BiodesixBDSX | 3.0% | $6m | 286,804 | Held |
| Stoke TherapeuticsSTOK | 2.7% | $6m | 178,110 | -15% |
| OvintivOVV | 2.6% | $6m | 107,500 | Held |
| Nektar TherapeuticsNKTR | 2.6% | $6m | 81,000 | +161% |
| Corcept TherapeuticsCORT | 2.3% | $5m | 57,200 | +21% |
| Neurocrine BiosciencesNBIX | 2.1% | $5m | 27,190 | Held |
| Prothena Corp PublicPRTA | 2.1% | $4m | 449,019 | Held |
| Acadia PharmaceuticalsACAD | 2.0% | $4m | 171,000 | Held |
| Protagonist TherapeuticsPTGX | 2.0% | $4m | 35,018 | Held |
| Compass TherapeuticsCMPX | 1.7% | $4m | 1,675,000 | +14% |
| Relmada TherapeuticsRLMD | 1.3% | $3m | 408,100 | Held |
| Alkermes plc.ALKS | 1.2% | $3m | 50,000 | Held |
| Halozyme TherapeuticsHALO | 1.2% | $3m | 33,251 | +229% |
| Celldex TherapeuticsCLDX | 1.2% | $3m | 69,900 | Held |
| CytokineticsCYTK | 1.2% | $3m | 30,000 | Held |
| Olema PharmaceuticalsOLMA | 1.2% | $2m | 199,000 | -9% |
| Vera TherapeuticsVERA | 1.2% | $2m | 57,758 | +31% |
| United TherapeuticsUTHR | 1.1% | $2m | 4,506 | Held |
| Zenas BioPharmaZBIO | 1.1% | $2m | 93,601 | +34% |
| uniQureQURE | 1.1% | $2m | 50,697 | -50% |
| Pacific Biosciences of CaliforniaPACB | 1.1% | $2m | 1,350,000 | -10% |
| Abivax SAABVX | 1.1% | $2m | 17,000 | New |
| Vir BiotechnologyVIR | 1.0% | $2m | 220,000 | New |
| BiogenBIIB | 0.9% | $2m | 9,000 | +80% |
| EQTEQT | 0.9% | $2m | 34,619 | Held |
| BioAge LabsBIOA | 0.8% | $2m | 69,000 | New |
| Travere TherapeuticsTVTX | 0.8% | $2m | 29,000 | Held |
| Quidel | 0.7% | $2m | 89,377 | +8% |
| Axsome TherapeuticsAXSM | 0.7% | $1m | 6,000 | Held |
| Foghorn TherapeuticsFHTX | 0.6% | $1m | 281,937 | Held |
| Bicycle TherapeuticsBCYC | 0.6% | $1m | 313,616 | -32% |
| Structure TherapeuticsGPCR | 0.6% | $1m | 24,000 | -76% |
| Xenon PharmaceuticalsXENE | 0.6% | $1m | 21,032 | Held |
| Novo Nordisk A SNVO | 0.5% | $1m | 24,000 | New |
| Freeport-McMoRanFCX | 0.5% | $1m | 18,035 | Held |
| ImmunomeIMNM | 0.5% | $1m | 50,000 | Held |
| PharvarisPHVS | 0.5% | $1m | 29,847 | Held |
| HarrowHROW | 0.5% | $1m | 24,000 | Held |
| AdageneADAG | 0.5% | $1m | 240,000 | New |
| Definium TherapeuticsDFTX | 0.4% | $940,800 | 20,000 | New |
| Silence TherapeuticsSLN | 0.4% | $781,974 | 71,218 | New |
| BridgeBio PharmaBBIO | 0.3% | $651,030 | 8,741 | Held |
| 4D Molecular TherapeuticsFDMT | 0.3% | $645,117 | 48,505 | New |
| UroGen PharmaURGN | 0.3% | $606,722 | 16,487 | New |
| Phathom PharmaceuticalsPHAT | 0.3% | $596,750 | 55,000 | -72% |
| Camp4 TherapeuticsCAMP | 0.2% | $524,400 | 120,000 | New |
| SavaraSVRA | 0.2% | $492,800 | 80,000 | New |
| Candel TherapeuticsCADL | 0.2% | $491,887 | 47,756 | -20% |
| AltimmuneALT | 0.2% | $464,150 | 152,681 | New |
| COMPASS PathwaysCMPS | 0.2% | $424,500 | 30,000 | -92% |
| Karyopharm TherapeuticsKPTI | 0.2% | $419,641 | 42,952 | -49% |
| Cullinan TherapeuticsCGEM | 0.2% | $364,200 | 20,000 | Held |
| Trinity CapitalTRIN | 0.2% | $357,800 | 20,000 | Held |
| Capricor TherapeuticsCAPR | 0.2% | $345,596 | 14,352 | New |
| Castle BiosciencesCSTL | 0.1% | $309,668 | 12,984 | Held |
| InvivydIVVD | 0.1% | $298,601 | 342,275 | New |
| Grace TherapeuticsGRCE | 0.1% | $272,400 | 120,000 | +140% |
| Kayne Anderson BDCKBDC | 0.1% | $270,600 | 20,000 | Held |
| Voyager TherapeuticsVYGR | 0.1% | $263,015 | 75,147 | Held |
| PulmonxLUNG | 0.1% | $260,706 | 200,543 | -20% |
| Ocular TherapeutixOCUL | <0.1% | $202,832 | 20,655 | -94% |
| Kyntra BIOKYNB | <0.1% | $170,373 | 22,566 | Held |
| ElutiaELUT | <0.1% | $161,726 | 165,094 | Held |
| Quoin PharmaceuticalsQNRX | <0.1% | $96,800 | 20,000 | Held |
| LipocineLPCN | <0.1% | $42,783 | 16,712 | -85% |
| DocGoDCGO | <0.1% | $20,160 | 39,062 | Held |
| Gossamer BioGOSS | <0.1% | $2,992 | 18,176 | Held |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 112.4% since 30 June 2025.
Where the money is
Health care60.3%
Technology32.3%
Energy3.5%
Materials0.5%
Other3.4%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.